| 52.86 1.13 (2.18%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 68.31 | 1-year : | 79.79 |
| Resists | First : | 58.49 | Second : | 68.31 |
| Pivot price | 54.81 |
|||
| Supports | First : | 49.05 | Second : | 43.22 |
| MAs | MA(5) : | 53.42 |
MA(20) : | 53.8  |
| MA(100) : | 47.97 |
MA(250) : | 42.14 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 26.3 |
D(3) : | 37.5 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 58.49 | Low : | 27.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SRRK ] has closed above bottom band by 19.0%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.32 - 53.69 | 53.69 - 53.98 |
| Low: | 50.88 - 51.27 | 51.27 - 51.58 |
| Close: | 52.34 - 52.96 | 52.96 - 53.43 |
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Sat, 18 Jul 2026
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
Sat, 18 Jul 2026
Leerink Partners Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK) - The Globe and Mail
Fri, 17 Jul 2026
11 New Hires Get Scholar Rock Equity Awards Covering 118,586 Shares - Stock Titan
Thu, 16 Jul 2026
Scholar Rock (SRRK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Thu, 16 Jul 2026
Scholar Rock (SRRK) Q3 2025 earnings summary - Quartr
Thu, 16 Jul 2026
Scholar Rock schedules Aug. 6 webcast before markets open - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 120 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 117.1 (%) |
| Shares Short | 18,380 (K) |
| Shares Short P.Month | 16,430 (K) |
| EPS | -3.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.3 % |
| Return on Equity (ttm) | -139 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.77 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -303 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -15.64 |
| PEG Ratio | 0 |
| Price to Book value | 22.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|